Pinned Tweet
Our new webinar series will confront the hard truths facing the UK #medicalcannabis sector. Our first session will ask what we can learn from Australia's experience. Submit questions to our expert panel now by replying to this tweet
This new task force is initially supported by seven industry partners and will be consulting on its plans in the coming months with a view to producing its first strategy paper to the new government in July. The group will be formally constituted this summer.
. @crdguk aims to build a robust ecosystem by integrating universities, research institutions, investors, businesses, and the NHS – driving innovation and development, nurturing top talent and fostering advances in healthcare.
Our ambition is to develop and implement a comprehensive strategy to transform the UK into the global leader in cannabinoid research and medicine development 2/
As an industry in its infancy, the UK's #medicalcannabis sector needs a voice
That's why we created the Medical Cannabis Journal – to educate, provide a rallying point, and seed the debates the sector must have to support sustainable growth medicalcannabisjournal.subst…
Our first articles garnered a strong response, and we're looking to build on that. So if you're working in this space and have something to say, get in touch with [email protected] and let us know
MCAired is a webinar series for growing the #medicalcannabis sector in the UK.
The first episode will focus on Australia, asking what lessons the UK medical cannabis industry can learn from the country's successes and mistakes.
So what exactly will we be looking at?
And finally, is there anything we are not doing, that Australia is, that would help improve the UK situation within current UK regulations?
Find out more by following us on @LinkedIn through this link: linkedin.com/feed/update/urn…
The best estimates put UK #medicalcannabis patient numbers at 32,000. Australia, with half the population, has 320,000. The question is, why?
Join our upcoming webinar series to find out why

